116632-23-6

Basic information

• Product Name: no
• Synonyms: Phenol, 3-broMo-5-nitro-;3-Bromo-5-hydroxynitrobenzene;3-Bromo-5-nitrophenol 97%;Phenol, 3-bromo-5-nitro- (Related Reference);3-Bromo-5-nitrophenol96%
• CAS NO: 116632-23-6
• Molecular Formula: C₆H₄BrNO₃
• Molecular Weight: 218.00486
• Mol File: 116632-23-6.mol

Chemical Properties

• Melting Point: 145 °C
• Boiling Point: 310.383 °C at 760 mmHg
• Flash Point: 141.515 °C
• Appearance: /
• Density: 1.881 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.38±0.10(Predicted)
• CAS DataBase Reference: no(CAS DataBase Reference)
• NIST Chemistry Reference: no(116632-23-6)
• EPA Substance Registry System: no(116632-23-6)

Safety Data

• Hazardous Substances Data: 116632-23-6(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Bromo-5-nitrophenol is utilized as a reagent in organic synthesis for its ability to participate in a range of chemical reactions, contributing to the formation of diverse organic compounds.
Used in Pharmaceutical Production:
As an intermediate, 3-Bromo-5-nitrophenol plays a crucial role in the manufacturing process of various pharmaceuticals, aiding in the synthesis of medicinally relevant molecules.
Used in Pesticide Formulation:
3-Bromo-5-nitrophenol is employed in the production of pesticides, where it serves as a key component in the formulation of effective and targeted pest control agents.
Used in Dye Manufacturing:
3-Bromo-5-nitrophenol is also used as an intermediate in the creation of dyes, contributing to the coloration and properties of various dye products.
Used in Environmental Management:
Given its classification as a hazardous substance and potential environmental pollutant, 3-Bromo-5-nitrophenol requires careful handling and disposal to mitigate its impact on the ecosystem and prevent harm to the environment.

Upstream product

• 121-88-0 5-Nitro-2-aminophenol 
• 915156-09-1 2-amino-3-bromo-5-nitro-phenol 
• 116296-08-3 acetic acid-(3-hydroxy-5-nitro-anilide) 
• 586-10-7 3-methoxy-5-nitroaniline 
• 586-11-8 3,5-dinitrophenol 
• 6311-60-0 3,5-dibromonitrobenzene 
• 618-64-4 3-Amino-5-nitro-phenol 
• 10035-10-6 hydrogen bromide 
• 16618-67-0 3-bromo-5-nitroanisole 

Downstream Products

• 936844-08-5 1-bromo-3-{2-[2-(2-methoxyethoxy)ethoxy]ethoxy}-5-nitrobenzene 
• 1610450-56-0 3-ethynyl-5-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)aniline 
• 1610450-55-9 1-ethynyl-3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrobenzene 
• 1610450-54-8 triisopropyl((3-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-5-nitrophenyl)ethynyl)silane 
• 1610449-80-3 1-(3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-((2-((3-ethynyl-5-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)phenyl)amino)pyrimidin-4-yl)oxy)naphthalen-1-yl)urea 
• 1372546-35-4 1-[5-[2-(ethylcarbamoylamino)-7-(2-pyridyl)-1,3-benzothiazol-5-yl]pyrimidin-2-yl]-4-phenyl-piperidine-4-carboxylic acid 
• 1459773-17-1 1-[5-benzyloxy-7-[4-(morpholinomethyl)-2-pyridyl]-1,3-benzothiazol-2-yl]-3-ethyl-urea 
• 1447811-48-4 (R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-((R,E)-3-methoxyhepta-4,6-dienamido)-5-(methoxymethoxy)phenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-((E)-2-methylbut-2-enamido)propanoate 
• 1447811-47-3 (R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-((E)-2-methylbut-2-enamido)propanoate 
• 1447811-46-2 (R)-(3E,6S,7S,8R,9Z)-8-((4-methoxybenzyl)oxy)-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-((E)-2-methylbut-2-enamido)propanoate 
• 98873-83-7 (+)-trienomycin A 
• 1447811-38-2 (R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-((R,E)-3-methoxyhepta-4,6-dienamido)-5-(methoxymethoxy)phenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-(cyclohexanecarboxamido)propanoate 
• 1447811-45-1 (R)-(3E,6S,7R,8R,9Z)-8-hydroxy-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl 2-(cyclohexanecarboxamido)propanoate 
• 1447811-37-1 (R)-((3E,6S,7S,8R,9Z)-8-(4-methoxybenzyloxy)-12-(3-(methoxymethoxy)-5-nitrophenyl)-7,9-dimethyldodeca-1,3,9-trien-6-yl) 2-(cyclohexanecarboxamido)propanoate 

Related news

Research paperChemical effect of no (cas 116632-23-6) on CH4 oxidation during combustion in O2/no (cas 116632-23-6) environments08/16/2019

The effect of NO on methane oxidation in O2/NO combustion atmosphere was investigated using reactive molecular dynamics (RMD) calculations. It has been observed that, the conversion of NO could accelerate the oxidation of CH4. To provide a detailed description for this phenomenon, the correspond...detailed

Nitrogen Defect Structure and no (cas 116632-23-6)+ Intermediate Promoted Photocatalytic no (cas 116632-23-6) Removal on H2 Treated g-C3N408/15/2019

By heating g-C3N4 powder in the hydrogen atmosphere, nitrogen defects were introduced into the framework of g-C3N4 where the nitrogen atoms in g-C3N4 were reacted and partially removed with hydrogen. The effects of nitrogen defects on the electronic structure, optical properties, generation of r...detailed

Relevant articles and documents

PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the same, and a pharmaceutical use of the pyrimidine compound for the prevention or treatment of cancer.

IMIDAZOPYRIDAZINE COMPOUND

The present invention relates to an imidazopyridazine compound having cell growth inhibitory activity, and a pharmaceutical composition for preventing or treating cancer or a tumor including the same. The imidazopyridazine compound of Chemical Formula 1 according to the present invention has excellent cell growth inhibitory activity, and thus can be favorably used as a preventive or therapeutic agent for cancer or a tumor.

Antibacterial Compounds

The present invention provides a compound of the following formula, salts, racemates, diastereomers, enantiomers, esters, carbamates, phosphates, sulfates, deuterated forms and prodrugs thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

Design, synthesis and biological evaluation of α-substituted isonipecotic acid benzothiazole analogues as potent bacterial type II topoisomerase inhibitors

The discovery and optimisation of a new class of benzothiazole small molecules that inhibit bacterial DNA gyrase and topoisomerase IV are described. Antibacterial properties have been demonstrated by activity against DNA gyrase ATPase and potent activity against Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes and Haemophilus influenzae. Further refinements to the scaffold designed to enhance drug-likeness included analogues bearing an α-substituent to the carboxylic acid group, resulting in excellent solubility and favourable pharmacokinetic properties.

ANTIBACTERIAL COMPOUNDS

The present invention provides a compound of the following formula and salts thereof: Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

TRPV4 ANTAGONISTS

The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME

Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure where Q is and R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.

2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES

The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition.

ANTIBACTERIAL COMPOSITIONS

Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1 ; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein R is hydrogen, -CN or C1-C3 alkyl; X is -C(=O)NR6-, -S(O)NR6-, -C(=O)O- or -S(=O)O- wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -Cyc, or -( C1-C3 alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms; Z is N or CH, or CF; R2 and R3 are as defined in the description.

INHIBITORS OF MATRIX METALLOPROTEINASES

The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.